Paul Liknaitzky

Dr. Paul Liknaitzky

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Addictive Behaviors
Verified
Journal Article
Closed access
RORenee O'DOnnell
Renee O'DOnnell
BRBen Richardson
Ben Richardson
MFMatthew Fuller-Tyszkiewicz
Matthew Fuller-Tyszkiewicz
PLPaul Liknaitzky
Paul Liknaitzky
LALilani Arulkadacham
Lilani Arulkadacham
PSPetra Staiger
Petra Staiger

24 November 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
PSPetra Staiger
Petra Staiger
RORenee O'Donnell
Renee O'Donnell
PLPaul Liknaitzky
Paul Liknaitzky
RBRachel Bush
Rachel Bush
JMJoanna Milward
Joanna Milward
Background: Mobile apps for problematic substance use have the potential to bypass common barriers to treatment seeking. Ten years following the release of the first app targeting problematic tobacco, alcohol, and illicit drug use, their effectiveness, use, and acceptability remains unclear. Objective: This study aims to conduct a systematic literature review of trials evaluating mobile app interventions for problematic tobacco, alcohol, and illicit drug use. Methods: The review was conducted according to recommended guidelines. Relevant databases were searched, and articles were included if the mobile app study was a controlled intervention trial and reported alcohol, tobacco, or illicit drug consumption as outcomes. Results: A total of 20 studies met eligibility criteria across a range of substances: alcohol (n=11), tobacco (n=6), alcohol and tobacco (n=1), illicit drugs (n=1), and illicit drugs and alcohol (n=1). Samples included the general community, university students, and clinical patients. The analyzed intervention sample sizes ranged from 22 to 14,228, and content was considerably diverse, from simple stand-alone apps delivering self-monitoring or psychoeducation to multicomponent apps with interactive features and audio content, or used as adjuncts alongside face-to-face treatment. Intervention duration ranged from 1 to 35 weeks, with notifications ranging from none to multiple times per day. A total of 6 of the 20 app interventions reported significant reductions in substance use at post or follow-up compared with a comparison condition, with small to moderate effect sizes. Furthermore, two other app interventions reported significant reductions during the intervention but not at post treatment, and a third reported a significant interaction of two app intervention components. Conclusions: Although most app interventions were associated with reductions in problematic substance use, less than one-third were significantly better than the comparison conditions at post treatment. A total of 5 out of the 6 apps that reported intervention effects targeted alcohol (of those, one targeted alcohol and illicit drugs and another alcohol and tobacco) and 1 targeted tobacco. Moreover, 3 out of 6 apps included feedback (eg, personalized) and 2 had high risk of bias, 1 some risk, and 3 low risk. All 6 apps included interventions of 6 weeks or longer. Common study limitations were small sample sizes; risk of bias; lack of relevant details; and, in some cases, poorly balanced comparison conditions. Appropriately powered trials are required to understand which app interventions are most effective, length of engagement required, and subgroups most likely to benefit. In sum, evidence to date for the effectiveness of apps targeting problematic substance use is not compelling, although the heterogeneous comparison conditions and trial designs across studies limit the ability to compare efficacy between apps. We discuss potential approaches that can help ascertain whether the promise of mobile app interventions for problematic substance use can be fulfilled.

16 March 2021 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
JPJake E Payne
Jake E Payne
RCRichard Chambers
Richard Chambers
PLPaul Liknaitzky
Paul Liknaitzky

21 March 2021 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
DPDaniel Perkins
Daniel Perkins
JSJerome Sarris
Jerome Sarris
SRSusan Rossell
Susan Rossell
YBYvonne Bonomo
Yvonne Bonomo
DFDavid Forbes
David Forbes
DCDavid Castle
David Castle
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on Psychedelics’ recently released by the Royal Australian and New Zealand College of Psychiatrists and note subsequent developments including the application for down-scheduling of psilocybin and 3,4-methylenedioxymethamphetamine presently being considered by the Therapeutic Goods Administration and approvals for access via the Special Access Scheme. We suggest that this field is worthy of rigorous research to assess potential benefits, address safety parameters and clarify therapeutic mechanisms. To this end, we outline recent research findings, provide an overview of current knowledge relating to mechanisms of action and discuss salient aspects of the psychedelic-assisted psychotherapy treatment model. The sum of this research points towards medicinal psychedelics as a potential new class of psychiatric treatments when used within a medically supervised framework with integrated psychotherapeutic support. However, before widespread translation into clinical use can occur, appropriately designed and sufficiently powered trials are required to detect both potential positive and negative outcomes. Unique safety and regulatory challenges also need to be addressed. As for any new medical therapy, psychedelic research needs to be conducted in a rigorous manner, through the dispassionate lens of scientific enquiry. Carte blanche availability to practitioners, without specific protocols and appropriate training, would be potentially harmful to individuals and detrimental to the field.

26 April 2017 in Cognitive Therapy and Research
Verified
Journal Article
Closed access
PDF file
PLPaul Liknaitzky
Paul Liknaitzky
LSLuke D. Smillie
Luke D. Smillie
NANicholas B. Allen
Nicholas B. Allen

3 April 2019 in Drug and Alcohol Review
Verified
Journal Article
Closed access
PDF file
ACAshlee Curtis
Ashlee Curtis
BVBrian Vandenberg
Brian Vandenberg
Richelle MayshakRichelle Mayshak
Richelle Mayshak
KCKerri Coomber
Kerri Coomber
SHShannon Hyder
Shannon Hyder
PMPeter G. Miller
Peter G. Miller